Reports Q2 revenue $5.3M, consensus $4.96M. “We delivered tremendous progress across our business in the first half of 2025, setting the stage for a transformative period ahead for uniQure (QURE),” said Matt Kapusta, chief executive officer of uniQure. “With alignment from the FDA on a biological license application pathway and pivotal topline data expected in September, AMT-130 is well-positioned to potentially become the first disease-modifying therapy for people living with Huntington’s disease.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- QURE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- uniQure Shareholders Approve Key Proposals at Annual Meeting
- uniQure appoints Kylie O’Keefe as chief customer, strategy officer
- Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint
- Positive Outlook for uniQure’s AMT-130 Program Drives Buy Rating Amid Regulatory Advancements and Robust Clinical Framework